Home›People›Bruce Booth
BB

Bruce Booth

Atlas Venture partner and Matchpoint Therapeutics chairman.

DirectorPublic company
Updated Nov 20, 2026·Latest SEC filing Nov 20, 2026·Suggest an edit

About Bruce Booth

Booth is an Atlas Venture partner focused on finding and developing new medicines and drug technology platforms. He also chairs Matchpoint Therapeutics. Matchpoint develops small-molecule medicines for immune diseases. He was the founding chief executive of Kymera Therapeutics and Nimbus Therapeutics. Before joining Atlas in 2005, he worked as a consultant at McKinsey & Company and an investor at Caxton Health Holdings. He has written about biotechnology and venture capital at LifeSciVC since 2011. During the winter, he volunteers as a coach with New England Disabled Sports. He holds a doctorate in molecular immunology from Oxford University and a B.S. in biochemistry, summa cum laude, from Penn State.

He chairs Kymera Therapeutics, Nimbus Therapeutics and HotSpot Therapeutics. He also chairs Matchpoint and Spolia Therapeutics. He serves on the Lifordi Immunotherapeutics and Sionna Therapeutics boards. He also serves on the Appalachian Mountain Club board. He previously served on boards of acquired Atlas companies. Celgene acquired Avila. Bial acquired Lysosomal Therapeutics. Takeda acquired Nimbus Lakshmi. BMS acquired Padlock Therapeutics. Alkermes acquired Rodin Therapeutics. Biogen acquired Stromedix. Sanofi acquired Vigil Neuroscience.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Bruce Booth in the role, so the role may have started earlier or lasted longer.

Sionna Therapeutics, Inc. Current
Director
2025 – Present · Public company (SION)
Matchpoint Therapeutics Inc. Current
Chairman; Partner, Atlas Venture
2022 – Present · Watertown, MA
Matchpoint develops oral drugs that bind hard-to-treat protein targets in immune diseases.
Kymera Therapeutics, Inc. Current
founding CEO
chairman
2020 – Present · Public company (KYMR)
Atlas Venture Current
Partner
2005 – Present
Nimbus Therapeutics Current
founding CEO
chairman
New England Disabled Sports Current
coach
HotSpot Therapeutics Current
chairman
Spolia Therapeutics Current
chairman
Lifordi Immunotherapeutics Current
board member
Appalachian Mountain Club Current
board member
Vigil Neuroscience, Inc.
Director
2022 – 2025 · Public company (VIGL)
Tectonic Therapeutic, Inc.
Director
2018 – 2023 · Public company (TECX)
Dianthus Therapeutics, Inc.
Director
2018 – 2022 · Public company (DNTH)
Cogent Biosciences, Inc.
Director
2018 – 2020 · Public company (COGT)
Viridian Therapeutics, Inc.
Director
2017 – 2018 · Public company (VRDN)
Larimar Therapeutics, Inc.
Director and 10% owner
2014 – 2018 · Public company (LRMR)
McKinsey & Company
consultant
2005
Caxton Health Holdings
investor
2005
Avila Therapeutics
board member
Lysosomal Therapeutics
board member
Nimbus Lakshmi
board member
Padlock Therapeutics
board member
Rodin Therapeutics
board member
Stromedix
board member
AVROBIO
Chairman of the Board of Directors
Magenta Therapeutics
Class III Director

Key Colleagues at Startups

The people Bruce Booth works with at each company, as listed on that company's latest Form D.

Matchpoint Therapeutics Inc. · Form D, Nov 20, 2026
Andre Turenne
Andre Turenne
Director; President & Chief Executive Officer
BM
Brian Matesic
Director; Principal, Norwest
KP
Kanishka Pothula
Director; Managing Partner, Nextech
JH
Jason Hafler
Director; Managing Director, Sanofi Ventures
DB
Daniel Becker
Director; Managing Director, Access Biotechnology
DN
Jared Cumming
Jared Cumming
Chief Scientific Officer
John O'Malley
John O'Malley
Chief Medical Officer

Bruce Booth in the News

Sources

  1. SECMatchpoint Therapeutics Inc. Form D, filed Nov 20, 2026
  2. SECForms 3, 4 and 5 filed by Bruce Booth (SEC filer 1451612)
  3. P3AVROBIO agreement
  4. P4Magenta Therapeutics certificate passage